Efficacy and safety of thioguanine as maintenance treatment for IBD

  • Bayoumy AB & al.
  • BMC Gastroenterol
  • 11 Sep 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Low-dose thioguanine (TG; ≤40 mg/day) can be effective and well-tolerated in more than 50% of difficult-to-treat patients with inflammatory bowel disease (IBD) failing conventional thiopurine therapy (azathioprine [AZA]/mercaptopurine [MP]) and other immunomodulation or biological therapy.
  • Hepatotoxicity was not common and the incidence rate of nodular regenerative hyperplasia (NRH) was within the background incidence.

Why this matters

  • Findings warrant future prospective trial to further establish the role of TG in patients with IBD as first-line or rescue treatment.

Study design

  • This retrospective, multicentre study included 193 patients with IBD (57% female and 64% Crohn’s disease) who had failed prior treatment with conventional thiopurine and other immunomodulation or biological therapy and were subsequently treated with TG as rescue monotherapy between 2003 and 2019.
  • Clinical response, adverse events, laboratory results, imaging, and liver biopsies were collected.
  • Funding: None.

Key results

  • The median daily dose of TG was 20 mg (range, 20-40 mg); median treatment duration was 23 months (interquartile range [IQR], 10-47 months); and the median follow-up time was 36 months (IQR, 22-53 months).
  • Clinical response at 6 and 12 months of TG therapy was seen in 71% (n=137) and 65% (n=125) of patients, respectively.
  • 54% of patients remained on TG until the end of follow-up.
  • Adverse events mainly included elevated liver function tests (6%), myelotoxicity (7%), and rash (5%).
  • Liver biopsies were performed in 33 patients (17%); NRH was histologically diagnosed in two patients and 2 other patients developed non-cirrhotic portal hypertension.
  • The median 6-thioguanine nucleotides and thiopurine methyltransferase levels were 953 (IQR, 145-1761) pmoL/8×105 RBC and 47 (IQR, 34.5-96) mU/L, respectively.

Limitations

  • Retrospective design.